Title of Invention

NOVEL AMINOINDAZOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Abstract

A compound of formula (I) in which R3 is a (l-6C)alkyl, aryl, aryl( l-6C)alkyl, heteroaryl, heteroaryl( 1-6C)alkyl, aryl or heteroaryl fused to a (1-IOC) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONRlR2, CSNRIR2, COCRl, SO<sub>2</sub> RI or C(=NH)NRI radical; these radicals optionally being substituted by I or more substituents chosen from halogen, CN, NO<sub>2</sub>, NH2, OH, ORl, COOH, C(O)ORl, -0- C(O)Rl, NRlR2, NHC(O)RI, C(O)NRlR2, SRI, S(O)Rl, SO2Rl, NHSO<sub>2</sub>Rl, S02NRIR2; C(S)NRlR2, NHC(S)RI, -O-SO<sub>2</sub>Rl, -SO<sub>2</sub>-O-RI, aryl, heteroaryl, formyl, oxo, tritluorometh:l. trifluoromethylsultanyl, tritluoromethoxy or (1- 6C)alkyl: R5 is an aryl optionally substituted by 1 or more substituents chosen from. halogen, .CN. 1\"0:, NH:.. OH. OR lO, COOH, C(O)ORIO, -0-C(O)RI0, NRIORll, NHC(O)RIO, C(O)NRlORll. NHC(S)RIO, C(S)NRIORll, SRI0, S(O)RIO, S02RIO, NHS01RI0, SO21\"RI0Rll, -O-SOlRI0, -SO2-0-RI0, .aryl, heteroaryl, formyl, trifluoromethyl, trifluoromethoxy or (1-6C)alkyl; R6 is a halogen, methyl. cyclopropyl, CN, OH, methoxy, trifluoromethyl, ethylenyl, acetylenyl, trifluoromethoxy, NO2, NH<sub>2</sub> or NMe2 radical; RI, R2 are, independently of one another, a hydrogen, (1-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (I-6C)alkyl, (1-6C)alkoxy, CN. NO<sub>2</sub>, NH<sub>2</sub>, OH, COOH, COOalkyl, CONH<sub>2</sub>, formyl, oxo, trifluoromethyl or trifluoromethoxy; Rl and R2 can form a 5- or 6-membered ring which mayor may not have a heteroatom, such as 0, S or N: its racemates, enantiomers or diastereoisomers and. their mixtures, its tautomers and its pharmaceutically acceptable salts.

Full Text

Novel aminoindazole deR1vatives as medicaments and pharmaceutical compositions including them The present invention relates to the use of deR1vatives of formula (I): or their pharmaceutically acceptable salts as kinase inhibitor. The subject matter of the invention is the use of the aminoindazole deR1vatives of formula (I) and their pharmaceutically acceptable salts in the preparation of pharmaceutical compositions intended to prevent and treat diseases which can result from an abnormal activity of kinases, such as, for example, those involved in neurodegenerative diseases, Alzheimer"s disease, Parkinson"s disease, frontopaR1etal dementia, corticobasal degeneration, Pick"s disease, strokes, cranial and spinal traumas and peR1pheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaR1es syndrome, syndrome X, immunodeficiency and cancer, the pharmaceutical compositions compR1sing the novel aminoindazole deR1vatives and their pharmaceutically acceptable salts and the novel aminoindazole deR1vatives and their pharmaceutically acceptable salts. The present invention relates to deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, NO2, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, SO2R1, NHSO2R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -O-SO2R1, -SO2-O-R1, aryl, heteroaryl, heterocycle, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 and R6 are, independently of one another, chosen from the following radicals halogen, CN, N02, NH2, OH, COOH, C(0)OR8, -0-C(0)R8, NR8R9, NHC(0)R8, C(0)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(0)R8, S02R8, NHSO2R8, S02NR8R9, -O-SO2R8, -SO2-O-R8, tR1fluoromethyl, tR1fluoromethoxy, (l-6C)alkyl, (l-6C)alkoxy, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or(l-6C)alkyl; Rl, R2, R8, R9, R10 and R11 are, independently of one another, a hydrogen, (1-6C)alkyl, aryl, alkenyl, alkynyl, heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl, tR1fluoromethoxy; Rl and R2 or R8 and R9 or R10 and Rl 1 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; and, when R3 is a 6-membered nitrogenous heteroaryl or a thiazolyl or an imidazolyl or an oxazolyl, then at least one of the R5 and R6 groups is an aryl which is optionally substituted by 1 or more substituents chosen from halogen, CN, NO2, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. More particularly, the present invention relates to deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, oxo, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (1-6C)alkyl; R5 is an aryl optionally substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, tR1fluoromethyl, ethylenyl, acetylenyl, tR1fluoromethoxy, N02, NH2 or NMe2 radical; Rl, R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, tR1fluoromethyl or tR1fluoromethoxy; Rl and R2 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention preferably relates to deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, oxo, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (1-6C)alkyl; R5 is a phenyl optionally substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10RH, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, tR1fluoromethyl, ethylenyl, acetylenyl, tR1fluoromethoxy, N02, NH2 or NMe2 radical; Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, tR1fluoromethyl or tR1fluoromethoxy; Rl and R2 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; to their racemates, enantiomers, diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention preferably relates to deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -SO2-O-R1, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 is a phenyl; R6 is a chloR1ne; Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl or tR1fluoromethoxy; to their isomers, to their mixtures, to their racemates, enantiomers, diastereoisomers or tautomers, and to their pharmaceutically acceptable salts. In the preceding definitions and those which follow, the (1-6C) alkyl radicals compR1se 1 to 6 carbon atoms in a straight- or branched-chain; the alkenyl radicals compR1se 2 to 6 carbon atoms and one to 3 conjugated or nonconjugated double bonds in a straight- or branched-chain; the alkynyl radicals compR1se 2 to 6 carbon atoms and one to 3 conjugated or nonconjugated tR1ple bonds in a straight- or branched-chain; the aryl radicals are chosen from phenyl, naphthyl or indenyl; the heteroaryl radicals compR1se 3 to 10 R1ng members, optionally compR1sing one or more heteroatoms chosen from oxygen, sulfur and nitrogen, in particular, thiazolyl, thienyl, pyrrolyl, pyR1dinyl, furyl, imidazolyl, oxazolyl, pyrazinyl, tetrazolyl, oxadiazolyl, thiadiazolyl, isoxadiazolyl, isothiadiazolyl, isothiazolyl, isoxazolyl, tR1azolyl, pyrazolyl or indolyl; the halogen radical is either chloR1ne, iodine, fluoR1ne or bromine; the polycycloalkyl radicals are chosen from adamantyl, quinuclidinyl, bornanyl, norbornanyl, bornenyl or norbornenyl; the heteroaryl radicals fused to a (1-10C) cycloalkyl are chosen from indanyl, isochromanyl, chromanyl, 1,2,3,4-tetrahydroisoquinolyl or 1,2,3,4-tetrahydroquinolyl; the heterocycle radicals compR1se 1 to 2 heteroatoms chosen from oxygen, sulfur or nitrogen and represent in particular pipeR1dinyl, morpholinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, isothiazolidinyl, thiazolidinyl, isoxazolidinyl, oxazolidinyl, piperazinyl, azetidinyl, 2-pipeR1done, 3-pipeR1done, 4-pipeR1done, 2-pyrrolidone or 3-pyrrolidone. The compounds of formula (I) exhibiting one or more asymmetR1c carbons and can therefore exist in the form of isomers, of racemates, of enantiomers and of diastereoisomers; the latter also form part of the invention, as do their mixtures. Mention may be made, among the compounds of formula (I) of use according to the invention, of the following compounds: N-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3,3 -dimethylbutyl)-5-phenyl-1 H-indazol-3 -amine 6-chloro-N-(3-phenylpropyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(cyclopropylmethyl)-5-phenyl-1 H-indazol-3 -amine 6-chloro-N-(cyclopentylmethyl)-5-phenyl-1 H-indazol-3 -amine 6-chloro-N-[3-(methylthio)propyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(phenylethyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(cyclohexylmethyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-propyl-5-phenyl-lH-indazol-3-amine 6-chloro-N-(2,2,3,3,4,4,4-heptafluorobutyl)-5-phenyl-lH-indazol-3-amine hydrate 6-chloro-N-(4,4,4-tR1fluorobutyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(4-methoxyphenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(phenylmethyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-[(4-cyanophenyl)methyl]-5-phenyl-lH-indazol-3-amine N-[(4-chlorophenyl)methyl]-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(3-methoxyphenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[[4-(tR1fluoromethoxy)phenyl]methyl]-5-phenyl-lH-indazol-3-amine N-[4-[[[6-chloro-5-phenyl-lH-indazol-3-yl]amino]methyl]phenyl]acetamide 6-chloro-N-[(3,5-dichlorophenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[4-(tR1fluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-N-[(4-fluorophenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-(4-methylphenoxy)phenylmethyl]-5-phenyl-lH-indazol-3-amine N-(2,2,3,3,4,4,4-heptafluorobutyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[3,5-bis(tR1fluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[3-(tR1fluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-N-[(6-methoxy-2-naphthyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(pentafluorophenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[[4-(methylthio)phenyl]methyl]-5-phenyl-lH-indazol-3-amine N-[(4-chloro-3-fluorophenyl)methyl]-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-(3,3,3-tR1fluoropropyl)-lH-indazol-3-amine 6-chloro-5-phenyl-N-(3-thienylmethyl)-lH-indazol-3-amine N-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-6-chloro-5-phenyl-lH-indazol-3-amine N-( 1,1 "-biphenyl-4-ylmethyl)-6-chloro-5-phenyl-1 H-indazol-3-amine 6-chloro-N-[[4-(dimethylamino)phenyl]methyl]-5-phenyl-lH-indazol-3-amine N-(2,2"-bithiophen-5-ylmethyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[l-(phenylmethyl)-lH-imidazol-2-yl]methyl]-lH-indazol-3-amine 6-chloro-N-[[l-methyl-lH-imidazol-2-yl]methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(l-methyl-lH-indol-3-yl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(5-memyl-2-fiiranyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-(lH-pyrrol-2-ylmethyl)-lH-indazol-3-amine 6-chloro-5-phenyl-N-[(lH-imidazol-2-yl)methyl]-lH-indazol-3-amine 6-chloro-5-phenyl-N-[( 1 H-imidazol-4-yl)methyl]-1 H-indazol-3-amine 6-chloro-5-phenyl-N-( 1 H-pyrazol-3 -ylmethyl)-1 H-indazol-3 -amine 6-chloro-N-[[2-methyl-lH-imidazol-4-yl]methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(3,5-dimethyl-l-phenyl-lH-pyrazol-4-yl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[2-phenyl-lH-imidazol-4-yl]methyl]-lH-indazol-3-amine 6-chloro-N-[[5-(4-chlorophenyl)-2-fiiranyl]methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[(l-methyl-lH-pyrrol-2-yl)methyl]-lH-indazol-3-amine 4-[5-[[[6-chloro-5-phenyl-lH-indazol-3-yl]amino]methyl]-2-fiiranyl]-benzenesulfonamide 6-chloro-5-phenyl-N-(3-thienylmethyl)-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[2-phenyl-lH-imidazol-4-yl]methyl]-lH-indazol-3-amine ethyl 2-[[[6-chloro-5-phenyl-lH-indazol-3-yl]amino]methyl]-5-(methylthio)-lH- imidazole-4-carboxylate 6-chloro-5-phenyl-N-[[5-[4-(tR1fluoromethyl)phenyl]-2-fliranyl]methyl]-lH-indazol-3-amine 6-chloro-5-phenyl-N-[2-(l-pipeR1dinyl)ethyl]-lH-indazol-3-amine 6-chloro-N-[2-(4-morpholinyl)ethyl]-5-phenyl-lH-indazol-3-amine N-(6-chIoro-5-phenyl-lH-indazol-3-yl)-N"-(3,5-dichIorophenyI)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(2-propenyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(phenylmethyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-phenoxyphenyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-[(4-methoxyphenyl)methyl]urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-[4-(tR1fluoromethyl)phenyl]urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-methoxyphenyl)urea N-(6-chloro-5-phenyl-1 H-indazol-3-yl)-N"-cyclohexylurea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-propylurea N-(6-chloro-5-phenyl-1 H-indazol-3-yl)-N"-(4-chlorophenyl)urea N-(6-chloro-5-phenyl-1 H-indazol-3-yl)-N"-(4-fluorophenyl)urea N-[6-chloro-5-phenyl-1 H-indazol-3-yl]-N"-(tR1cyclo[3.3.1.13,7]dec-1 -yl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-methylphenyl)urea N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methyl-benzenesulfonamide N-[6-chloro-5-phenyl-1 H-indazol-3 -yl]methanesulfonamide N-[6-chloro-5-phenyl-1 H-indazol-3-yl]-2-propanesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-2,2,2-tR1fluoroethanesulfonamide N-[6-chloro-5-phenyl-lH-mdazol-3-yl]-2-thiophenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]benzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-(tR1fluoromethyl)benzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-5-(3-isoxazolyl)-2-thiophenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-fluorobenzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methoxybenzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]benzenemethanesulfonamide N-[6-chloro-5-phenyl-1 H-indazol-3-yl]-1 -methyl-1 H-imidazole-4-sulfonamide N-[6-chloro-5-phenyl-1 H-indazol-3-yl]-4-( 1,1 -dimethylethyl)benzenesulfonamide N-[4-[[(6-chloro-5-phenyl-lH-indazol-3-yl)amino]sulfonyl]phenyl]acetamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methylbenzenemethanesulfonamide 6-chloro-N-(pentafluorophenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3,4-difluorophenyl)-5 -phenyl-1 H-indazol-3-amine 6-chloro-5-phenyl-N-(2,3,5,6-tetrafluorophenyl)-lH-indazol-3-amine 6-chloro-5-phenyl-N-(2,4,6-tR1fluorophenyl)-lH-indazol-3-amine 6-chloro-N-(4-fluorophenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-(tR1fluoromethyl)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[4-(tR1fluoromethyl)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-fluoro-5-(tR1fluoromethyl)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(4-nitrophenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3-nitrophenyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(3 -methoxyphenyl)- 5 -phenyl-1 H-indazol-3 -amine 6-chloro-N-(4-methoxyphenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N,5-diphenyl-1 H-indazol-3-amine 6-chloro-N-( 1 -pyR1dinyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(2-pyR1dinyl)-5-phenyl-1 H-indazol-3 -amine their isomers, their mixtures, their racemates, enantiomers, diastereoisomers or tautomers, and their pharmaceutically acceptable salts, and more particularly the following compounds: N-butyl-6-chloro-5-phenyl-lH-indazol-3-amine 3-(6-Chloro-5-phenyl-lH-indazol-3-ylamino)thiophene-2-carbonitR1le (6-Chloro-5-phenyl-lH-indazol-3-yl)(pyR1din-2-yl)amine (6-Chloro-5-phenyl-lH-indazol-3-yl)(5-nitropyR1din-2-yl)amine (6-Chloro-5-phenyl-lH-indazol-3-yl)(6-methoxypyR1din-2-yl)amine N-(6-Chloro-5-phenyl-1 H-indazol-3-yl)-N"-phenylurea 1 -(6-Chloro-5 -phenyl-1 H-indazol-3 -yl)-3 -(4-ethoxyphenyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3,4-dichlorophenyl)urea 3-[3-(6-Chloro-5-phenyl-lH-indazol-3-yl)ureido]propionic acid methyl ester l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(4-(dimethylamino)phenyl)urea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-isopropylurea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-cyclohexylurea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3-(tR1fluoromethyl)phenyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(2-(thiophen-2-yl)ethyl)urea 1 -(1,3-Benzodioxol-5-yl)-3-(6-chloro-5-phenyl-1 H-indazol-3-yl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3,5-dimethylisoxazol-4-yl)urea l-Benzyl-3-(6-chloro-5-phenyl-lH-indazol-3-yl)urea 1 -(6-Chloro-5 -phenyl-1 H-indazol-3 -yl)-3 -(phenethyl)thiourea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-[3-(4-methylpiperazin-1 -yl)propyl]urea 1 -(6-Chloro-5 -phenyl-1 H-indazol-3-yl)-3-( 3-(imidazol-1 -yl)propyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(2-hydroxyethyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-[3-(4-methylpiperazin-l-yl)propyl]urea Pyrrolidine-1 -carboxylic acid (6-chloro-5-phenyl-1 H-indazol-3-yl)amide (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid methyl ester (6-Chloro-5-phenyl-1 H-indazol-3-yl)urea (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid benzyl ester (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid allyl ester (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid isobutyl ester PipeR1dine-1 -carboxylic acid (6-chloro-5-phenyl-1 H-indazol-3-yl)amide 1 -(3 -(Azetidin-1 -yl)propyl)-3 -(6-chloro-5-phenyl-1 H-indazol-3 -yl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3-chloropropyl)urea 1 -(6,7-Difluoro-5-phenyl-1 H-indazol-3-yl)-3-(3-(imidazol-1 -yl)propyl)urea 1 -(3-Aminopropyl)-3-(6-chloro-5-phenyl-l H-indazol-3-yl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-[4-(4-(pyR1din-3-yl)imidazol-l-yl)-butyljurea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(2-(pyrrolidin-l-yl)ethyl)urea 2,5-Dimethylpyrrolidine-l-carboxylic acid (6-chloro-5-phenyl-l H-indazol-3 -yl)-amide N-(6-Chloro-5-phenyl-lH-indazol-3-yl)acetamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)-6-methoxypyrazine-2-carboxamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)benzamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)pyR1dine-2-carboxamidine N-(6-chloro-5-phenyl-lH-indazol-3-yl)-3-methoxybenzenesulfonamide their isomers, their mixtures, their racemates, enantiomers, diastereoisomers or tautomers, and their pharmaceutically acceptable salts, The invention also relates to the pharmaceutical compositions compR1sing, as active pR1nciple, a deR1vative of formula (I) in which R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from CN, NO2, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHSO2R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -SO2-O-R1, aryl, heteroaryl, heterocycle, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 and R6 are, independently of one another, chosen from the following radicals halogen, CN, N02, NH2, OH, COOH, C(0)OR8, -0-C(0)R8, NR8R9, NHC(0)R8, C(0)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(0)R8, S02R8, NHS02R8, S02NR8R9, -O-SO2R8, -SO2-O-R8, tR1fluoromethyl, tR1fluoromethoxy, (l-6C)alkyl, (l-6C)alkoxy, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, NO2, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or(l-6C)alkyl; Rl, R2, R8, R9, R10 and R11 are, independently of one another, a hydrogen, (1-6C)alkyl, aryl, alkenyl, alkynyl, heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2) formyl, tR1fluoromethyl, tR1fluoromethoxy; Rl and R2 or R8 and R9 or R10 and R11 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; and, when R3 is a 6-membered nitrogenous heteroaryl or a thiazolyl or an imidazolyl or an oxazolyl, then at least one of the R5 and R6 groups is an aryl which is optionally substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention relates more particularly to the pharmaceutical compositions compR1sing, as active pR1nciple, a deR1vative of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, oxo, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (1-6C)alkyl; R5 is an aryl optionally substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10RH, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, tR1fluoromethyl, ethylenyl, acetylenyl, tR1fluoromethoxy, NO2, NH2 or NMe2 radical; Rl, R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, tR1fluoromethyl or tR1fluoromethoxy; Rl and R2 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention preferably relates to the pharmaceutical compositions compR1sing, as active pR1nciple, a deR1vative of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)0R1, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 is a phenyl; R6 is a chloR1ne; Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl or tR1fluoromethoxy; to their isomers, to their mixtures, to their racemates, enantiomers, diastereoisomers or tautomers, and to their pharmaceutically acceptable salts. The present invention also relates to the use, as medicament, of the aminoindazole deR1vatives of the formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHSO2R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, heterocycle, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 and R6 are, independently of one another, chosen from the following radicals halogen, CN, N02, NH2, OH, COOH, C(0)OR8, -0-C(0)R8, NR8R9, NHC(0)R8, C(0)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(0)R8, SO2R8, NHSO2R8, S02NR8R9, -O-SO2R8, -SO2-O-R8, tR1fluoromethyl, tR1fluoromethoxy, (l-6C)alkyl, (l-6C)alkoxy, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R11, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or(l-6C)alkyl; Rl, R2, R8, R9, R10 and R11 are, independently of one another, a hydrogen, (1-6C)alkyl, aryl, alkenyl, alkynyl, heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl, tR1fluoromethoxy; Rl and R2 or R8 and R9 or R10 and Rl 1 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; and, when R3 is a 6-membered nitrogenous heteroaryl or a thiazolyl or an imidazolyl or an oxazolyl, then at least one of the R5 and R6 groups is an aryl which is optionally substituted by 1 or more substituents chosen from halogen, CN, NO2, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10R1I, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention relates more particularly to the use, as medicament, of the aminoindazole deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-1OC) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, oxo, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (1-6C)alkyl; R5 is an aryl optionally substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10R11, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10RH, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, tR1fluoromethyl, ethylenyl, acetylenyl, tR1fluoromethoxy, N02, NH2 or NMe2 radical; Rl, R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, tR1fluoromethyl or tR1fluoromethoxy; Rl and R2 can form a 5- or 6-membered R1ng which may or may not have a heteroatom, such as O, S or N; to their racemates, enantiomers or diastereoisomers and their mixtures, to their tautomers and to their pharmaceutically acceptable salts. The present invention preferably relates to the use, as medicament, of the aminoindazole deR1vatives of formula (I) in which: R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, S02R1, C(=NH)R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl; R5 is a phenyl; R6 is a chloR1ne; Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl or tR1fluoromethoxy; to their isomers, to their mixtures, to their racemates, enantiomers, diastereoisomers or tautomers, and to their pharmaceutically acceptable salts. The deR1vatives of formula (I) can be obtained from the corresponding 3-amino deR1vatives (V) for which the nitrogen in the 1 -position is optionally protected with a group Pr. Pr is a tR1methylsilylethoxymethyl, tosyl, mesyl or benzyl radical or the groups known for the protection of the NH groups of aromatic heterocycles as indicated in T.W. Greene, Protective Groups in Organic Synthesis, J. Wiley-Interscience Publication (1999) The 3-amino lH-indazoles of formula (II) can be obtained by reaction of a 2-fluorobenzonitrile with hydrazine hydrate or hydrochloride at reflux for 2 to 18 hours in an alcohol of ethanol or n-butanol type according to R.F. Kaltenbach, Bioorg. Med. The compounds for which R5 and R6 are, independently of one another, chosen from the following radicals: hydrogen, halogen, CN, N02, NH2, OH, COOH, C(0)OR8, -0-C(0)R8, NR8R9, NHC(0)R8, C(0)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(0)R8, S02R8, NHSO2R8, S02NR8R9, -O-SO2R8, -SO2-O-R8, trifluoromethyl, trifluoromethoxy, (l-6C)alkyl, (l-6C)alkoxy, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, cycloalkyl, alkenyl, alkynyl or adamantyl; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10Rll, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NRIORH, -O-SO2RIO, -SO2-O-RIO, aryl, heteroaryl, formyl, trifluoromethyl, trifluoromethoxy or (l-6C)alkyl; can be obtained by reactions involving the chemistry of palladium: Suzuki (A. Suzuki, Pure Appl. Chem., 63, 419-22 (1991), Stille (J. Stille, Angew. Chem., Int. Ed., 25, 508-24 (1986)), Heck (R. F. Heck, Org. React., 27, 345-90 (1982)), Sonogashira, (K. Sonogashira, Synthesis, 777 (1977)), Buckwald (S.L. Buckwald, Ace. Chem. Re., 3J_, 805 (1998)), from the corresponding halogenated deR1vatives. For this, it is necessary to protect the reactive functional groups. Thus, the OH, SH, COOH and NH2 functional groups must be protected before carrying out the coupling. The protective groups are introduced according to any method known to a person skilled in the art and in particular those descR1bed by T.W. Greene, Protective groups in Organic Synthesis, J. Wiley-Interscience Publication (1999). It is preferable to protect the nitrogen in the 1-position with groups such as tert-butoxycarbonyl or 1 silicon deR1vatives. The choice will preferably be made of a tert-butyldimefhylsilyl or tR1isopropylsilyl silyl group which can be removed by fluoR1de anions or with acetic acid and more particularly a tR1methylsilylethoxymethyl group which can be cleaved by tetrabutylammonium fluoR1de at reflux in solvents such as tetrahydrofuran or dioxane (J. P. Whitten, J. Org. Chem., 51, 1891 (1986); B. H. Lipshutz, Tetrahedron Lett., 4095 (1986)) or by 2N hydrochloR1c acid in methanol or ethanol at reflux. The deR1vatives protected in the 1-position with tR1methylsilylethoxymethyl are obtained by reacting the starting compound with tR1methylsilylethoxymethyl chloR1de in the presence of sodium hydR1de in a solvent, such as dimethylformamide, at ambient temperature (J. P. Whitten, J. Org. Chem., 51, 1891 (1986); M. P. Edwards, 1 Tetrahedron, 42, 3723 (1986)). Likewise, the 1-NH nitrogen functional group of the indazole will be protected by groups such as silyl deR1vatives, benzyl, carbamate or tosyl. For example, in the case where it would be desired to carry out coupling with palladium to a deR1vative halogenated in the 6-position, it will be necessary to protect the nitrogen in the 1- Deprotection is carR1ed out according to methods known to a person skilled in the art and descR1bed by T.W. Greene, Protective Groups in Organic Synthesis, J. Wiley-Interscience Publication (1999). For example, if the protective group in the 1-position is a tR1methylsilylethoxymethyl, it can be deprotected by reaction with When one of the R5 or R6 groups involved in the coupling using the chemistry of palladium itself compR1ses a reactive functional group, such as hydroxyl, amine, thiol or acid or generally includes a heteroatom, it is also necessary to protect the latter before carrying out the coupling with palladium. Thus, for example, a phenol functional group will be introduced in the protected form (O-benzyl, for example) from the chloR1nated deR1vative, the nitrogen in the 1-position being protected as The benzyl group will subsequently be removed, for example by treatment with tR1methylsilyl iodide at reflux in acetonitR1le. Protection can also be carR1ed out by a tR1methylsilylethoxymethyl group which can be cleaved by tetrabutylammonium fluoR1de at reflux in solvents such as tetrahydrofuran or dioxane. (J. P. Whitten, J. Org. Chem., 51, 1891 (1986); B. H. Lipshutz, Tetrahedron Lett., 4095 (1986)) or by 2N hydrochloR1c acid in methanol or ethanol at reflux. When R5 and R6 are, independently of one another, an aryl and a halogen, the aryl functional group is introduced from coupling with palladium to a brominated position, the nitrogen in the 1- and 3-positions being appropR1ately protected. Preferably, Pr represents a tR1rnethylsilylethoxymethyl and Pr" represents an n-butylcarbonyl group which forms, with the nitrogen, an n-butylamide. The stage of deprotecting the amide is carR1ed out in the presence of ethanolamine at reflux for one week in DMF. This cleavage can also be carR1ed out with stannous chloR1de in ethanol (R J GR1ffin, J. Chem. Soc. Perkin I, 1992, 1811-1819) or else sodium methoxide in methanol (Y. Furukawa, Chem. Pharm. Bull., 1968,16, 1076) or any other alkoxide in The compounds of formula (II) are the starting point for the preparation of a great vaR1ety of products obtained by reaction of the pR1mary amine functional group of the 3-aminoindazole in all the conventional reactions of this functional group, such as: alkylation, acylation, reactions with carbonyl deR1vatives followed by reduction, sulfonation, conversion to ureas or carbamates, arylation (Castro reaction or Buchwald reaction), and the like. The reduction amino of deR1vatives of deR1vative general formula (I) where R3 is H when Pr is tR1rnethylsilylethoxymethyl can be carR1ed out using boron deR1vatives, such as sodium tR1acetoxyborohydR1de, in dichloromethane in the presence of an aldehyde of type R1CHO under the conditions descR1bed in Organic Reactions, Vol. 59, 1-714 (E.Baxter, A.Reitz), or by the other reducing agents commonly used to reduce imines, to form products where R3 is (l-6C)alkyl, aryl(l-6C)alkyl, heteroaryl(l-6C)alkyl, heterocycloalkyl, cycloalkyl or polycycloalkyl, these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -O-SO2R1, -SO2-O-R1, aryl, heteroaryl, formyl, tR1fluoromethyl, tR1fluoromethylsulfanyl, tR1fluoromethoxy or (l-6C)alkyl. Condensations with deR1vatives general formula (I) where R3 is H with isocyanates of type OCNR1 can be carR1ed out in particular in tetrahydrofuran and according to the examples descR1bed in Comprehensive Organic Functional Group Transformations, Vol. 6 (KatR1tzky, Meth-Cohn, Rees 1995), to form products where R3 is CONR1R2 and Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl or tR1fluoromethoxy. Sulfonations of deR1vatives of general formula (I) where R3 is H can be carR1ed out from a sulfonyl chloR1de of Rl SO2CI type in the presence of a base (in particular tertiary amines, such as tR1ethylamine, or aromatic amines, such as pyR1dine) in a conventional solvent, such as, for example, dichloromethane, to form the products where R3 is SO2R1 and Rl is a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, tR1fluoromethyl or tR1fluoromethoxy. The compound IV where Pr is tR1methylsilylethoxymethyl is 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole and is obtained in the following way: 3-Amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole 1.63 cm3 of ethanolamine and then 2.24 g of potassium carbonate are added to 2.4 g of N-[5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide descR1bed hereinafter, in 75 cm3 of dimethylformamide and the mixture is heated at reflux for one week. The reaction medium is concentrated to dryness under reduced pressure and taken up in 250 cm3 of ethyl acetate and 100 cm3 of water. The organic phase is separated by settling and washed successively with 2 times 100 cm3 of water and 75 cm3 of sodium chloR1de solution. The organic phase is dR1ed over magnesium sulfate, filtered and then concentrated to dryness under reduced pressure (2 kPa, 50°C). The crude oil obtained is puR1fied by chromatography under an argon pressure of 50 kPa on a column of silica gel (particle size 40-60 urn; diameter 4cm), elution being carR1ed out with a cyclohexane/ethyl acetate (80/20 by volume) mixture and 35 cm3 fractions being collected. The fractions compR1sing the expected product are combined and evaporated under reduced pressure (2 kPa; 50°C). After drying (90 Pa; 45°C), 0.43 g of 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]-indazole is obtained in the form of a yellow oil. *H N.M.R. spectrum (300 MHz, (CD3)2SO, 8 in ppm): -0.05 (s, 9H), 0.83 (t, J = 8 Hz, 2H), 3.52 (t, J = 8 Hz, 2H), 5.49 (s, 2H), 5.75 (broad s, 2H), from 7.30 to 7.55 (mt, 5H), 7.77 (s, 1H), 7.81 (s, 1H). N-[5-Phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide is obtained in the following way: 821 mg of phenylboronic acid, 1.14 g of sodium carbonate in 30 cm3 of distilled water and, finally, 347 mg of tetrakis(tR1phenylphosphine)palladium are added to 2 g of N-[5-bromo-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide descR1bed hereinafter in 180 cm3 of dioxane. The mixture is heated at reflux for 90 minutes and is then allowed to return to 20°C in order to add 100 cm3 of ethyl acetate and 100 cm3 of distilled water. The organic phase is washed with 100 cm3 of a saturated aqueous sodium chloR1de solution, then separated by settling and dR1ed over magnesium sulfate. After filteR1ng through a sintered glass funnel, the filtrate is concentrated to dryness under reduced pressure (2 kPa; 50°C). The residue is puR1fied by chromatography under an argon pressure of 50 kPa on a column of silica gel (particle size 40-60 um; diameter 4.5 cm), elution being carR1ed out with a cyclohexane/ethyl acetate (80/20 by volume) mixture and 35 cm3 fractions being collected. The fractions compR1sing the expected product are combined and evaporated under reduced pressure (2 kPa; 50°C). After drying, 90 Pa; 45°C), 2 g of N-[5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide are thus obtained in the form of a yellow oil. "H N.M.R. spectrum (300 MHz, (CD3)2SO, 8 in ppm): -0.05 (s, 9H), 0.85 (t, J = 8 Hz, 2H), 0.92 (t, J = 7.5 Hz, 3H), 1.63 (mt, 2H), 2.38 (t, J = 7.5 Hz, 2H), 3.56 (t, J = 8 Hz, 2H), 5.70 (s, 2H), from 7.30 to 7.55 (mt, 5H), 7.91 (s, 1H), 7.99 (s, 1H), 10.59 (broad s, 1H). N-[5-Bromo-6-chloro-1 -[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide is obtained in the following way: 0.22 cm3 of pyR1dine is added to lg of N-[6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide descR1bed hereinafter in 15 cm3 of chloroform and then 0.14 cm3 of bromine is added. The mixture is stirred at 20°C for 24 hours and then 50 cm3 of dichloromethane and 50 cm3 of a saturated aqueous sodium sulfate solution are subsequently added. After stirR1ng for 10 minutes, the insoluble mateR1al is removed by filtration through a sintered glass funnel and the organic phase is washed with 50 cm3 of a saturated aqueous sodium chloR1de solution. The organic phase is separated by settling, dR1ed over magnesium sulfate, filtered and evaporated to dryness under reduced pressure (2 kPa; 45°C). The residue is puR1fied by chromatography under an argon pressure of 50 kPa on a column of silica gel (particle size 40-60 μm; diameter 3.5 cm), elution being carR1ed out with an ethyl acetate/cyclohexane (20/80 by volume) mixture and 35 cm3 fractions being collected. The fractions compR1sing the expected product are combined and evaporated under reduced pressure (2 kPa; 50°C). After drying (90 Pa; 45°C), 0.94 g of N-[5-bromo-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide is obtained in the form of a white solid melting at 130°C. "H N.M.R. spectrum (300 MHz, (CD3)2SO, 8 in ppm): - 0.08 (s, 9H), 0.82 (t, J = 8 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H), 1.66 (mt, 2H), 2.40 (t, J = 7.5 Hz, 2H), 3.52 (t, J = 8 Hz, 2H), 5.66 (s, 2H), 8.13 (s, 1H), 8.34 (s, 1H), 10.67 (broad s, 1H). N-[6-Chloro-1 -[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide is obtained in the following way: 3 g of N-(6-chloro-lH-indazol-3-yl)butanamide, in solution of 40 cm3 of dimethylformamide, are added to 606 mg of 60% sodium hydR1de in 20 cm3 of dimethylformamide. After having cooled to approximately 5°C, 2.68 cm3 of 2-(tR1methylsilyl)ethoxymethyl chloR1de in 10 cm3 of dimethylformamide are added. The temperature is allowed to return to approximately 21°C and the mixture is stirred for 2 hours. The reaction medium is subsequently evaporated under reduced pressure (2 kPa; 45°C). The residue is taken up in 200 cm3 of ethylacetate and in 100 cm3 of distilled water. Washing is again carR1ed out with 2 times 100 cm3 of distilled water and with 100 cm of a saturated aqueous sodium chloR1de solution. The organic phase is dR1ed over magnesium sulfate, filtered through a sintered glass funnel and then evaporated under reduced pressure (2 kPa; 50°C). The residue is puR1fied by chromatography under an argon pressure of 50 kPa on a column of silica gel (particle size 40-60 urn; diameter 4.5 cm), elution being carR1ed out with a cyclohexane/ethylacetate (80/20 by volume) mixture and 100 cm3 fractions being collected. The fractions compR1sing the expected product are combined and evaporated under reduced pressure (2 kPa; 50°C). After drying (90 Pa; 50°C), 3 g of N-[6-chloro-1 -[(2-tR1methylsilylethoxy)methyl]indazol-3-yl]butanamide are obtained in the form of a yellow oil. !H N.M.R. spectrum (300 MHz, (CD3)2SO, 5 in ppm): - 0.08 (s, 9H), 0.83 (broad t, J = 8 Hz, 2H), 0.96 (t, J = 7.5 Hz, 3H), 1.67 (mt, 2H), 2.40 (t, J = 7.5 Hz, 2H), 3.53 (t, J = 8 Hz, 2H), 5.66 (s, 2H), 7.16 (dd, J = 9 to 2 Hz, 1H), 7.86 (d, J = 2 Hz, 1H), 7.88 (d, J = 9 Hz, 1H), 10.53 (unresolved peak, 1H). N-(6-Chloro-1 H-indazol-3-yl)butanamide 0.47 cm3 of butyryl chloR1de is added to 750 mg of 3-amino-6-chloro-lH-indazole in 10 cm3 of pyR1dine after having cooled the reaction medium to approximately 3°C. The medium is then subsequently allowed to return to 19°C over 14 hours. The reaction medium is evaporated to dryness under reduced pressure (2 kPa; 40°C). The residue is taken up in 50 cm3 of ethyl acetate, in 50 cm3 of tetrahydrofuran and in 50 cm of distilled water. The organic phase is washed again with 50 cm of distilled water and with 50 cm3 of a saturated aqueous sodium chloR1de solution and then dR1ed over magnesium sulfate, filtered through a sintered glass funnel and evaporated under reduced pressure. The residue obtained is puR1fied by chromatography under an argon pressure of 50 kPa on a column of silica gel (particle size 40-60 urn; diameter 2.5 cm), elution being carR1ed out with cyclohexane/ethyl acetate (70/30 by volume) and 25 cm3 fractions being collected. The fractions compR1sing the expected product are combined and then evaporated under reduced pressure (2 kPa; 40°C). After drying (90 Pa; 45 °C), 200 mg of N-(6-chloro-lH-indazol-3-yl)butanamide are obtained in the form of a white solid melting at 230°C. !H N.M.R. spectrum (300 MHz, (CD3)2SO, 5 in ppm): 0.98 (t, J = 7 Hz, 3H), 1.67 (mt, 2H), 2.40 (t, J = 7 Hz, 2H), 7.08 (dd, J = 9 and 2 Hz, 1H), 7.52 (d, J = 2 Hz, 1H), 7.84 (d, J = 9 Hz, 1H), 10.39 (unresolved peak, 1H), from 12.50 to 13.00 (broad unresolved peak, 1H). 3-Amino-6-chloro-5-phenyl-lH-indazole is obtained from 3-amino-5-phenyl-6-chloro-1 -[(2-tR1methylsilylethoxy)methyl]indazole. 300 μl of 2N HC1 are added to 108.3 mg of the compound 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 4.7 ml of methanol. The reaction is placed under microwaves at 140°C for 150 seconds. The mixture is poured onto a saturated KH2PO4 solution and extraction is carR1ed out with AcOEt. The organic phases are dR1ed over anhydrous MgSCU, filtered and concentrated. The crude product obtained is puR1fied through silica and 63.5 mg of the compound 3-amino-6-chloro-5-phenyl-lH-indazole are obtained. The compounds of formula (I) are isolated and can be puR1fied by the usual known methods, for example by crystallization, chromatography or extraction. The compounds of formula (I) can optionally be converted to addition salts with an inorganic or organic acid by the action of such an acid in an organic solvent, such as an alcohol, ketone, an ether or a chloR1nated solvent. These salts also form part of the invention. Mention may be made, as examples of pharmaceutically acceptable salts, of the following salts: benzenesulfonate, hydrobromide, hydrochloR1de, citrate, ethanesulfonate, fumarate, gluconate, iodate, maleate, isethionate, methanesulfonate, methylenebis-p-oxynaphthoate, nitrate, oxalate, pamoate, phosphate, salicylate, succinate, sulfate, tartrate, theophyllineacetate and p-toluenesulfonate. The compounds of formula (I) are kinase inhibitors and are thus of use in the prevention and treatment of neurodegenerative diseases, Alzheimer"s disease, Parkinson"s disease, frontopaR1etal dementia, corticobasal degeneration, Pick"s disease, strokes, cranial and spinal traumas and peR1pheral neuropathies, obesity, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaR1es syndrome, syndrome X, immunodeficiency and cancer. The activities were determined by measuR1ng the inhibition of the phosphorylation of the tau protein in adult rat cortex sections. Cortex sections with a thickness of 300|j.m are prepared from male OFA rats (Iffa-Credo) aged 8-10 weeks, sacR1ficed by decapitation. They are incubated in 5 ml of DMEM medium compR1sing pyruvate and glucose 4.5 g/1 at 37°C for 40 min. The sections are subsequently washed twice with the medium, distR1buted in microtubes (50μl in 500μl of medium, with or without test compounds) and incubated at 37°C with stirR1ng. Two hours later, the expeR1ment is halted by centR1fuging. The sections are lyzed, sonicated and centR1fuged at 18300g for 15 min at 4°C. The concentration of proteins in the supernatant is determined by a commercial assay (BCA Protein Assay, Pierce) based on the Lowry method. The samples, denatured beforehand at 70°C for 10 min, are separated on 4-12% Bis-tR1s vertical gel in the presence of MOPS-SDS buffer and are electrotransferred onto a nitrocellulose membrane. Immunolabeling is carR1ed out with the monoclonal antibody AD2, which specifically recognizes the Ser3 96/404 phosphorylated epitopes of the tau protein. The immunoreactive proteins are visualized by addition of a second antibody directed against mouse IgGs and coupled to peroxidase and of a chemoluminescent substrate. The autoradiograms obtained are finally quantified using the "GeneTools" software from Syngene (GeneGnome, Ozyme) to determine an IC50 value. The compounds of formula (I) exhibit a highly advantageous activity and in particular some compounds have an IC50 value of less than 100 μM. The conditions for analysis of the products by LC/MS were produced on a Waters Alliance 2695 device for the LC part and a Waters-Micromass Platform II for the mass part. The following examples illustrate the invention without implied limitation. Example Al: N-butyl-6-chloro-5-phenyl-1 H-indazol-3-amine Stage 1: 24 mg of n-butyraldehyde and 113 mg of sodium tR1acetoxyborohydR1de are added to a solution of 100 mg of 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 5cm3 of methylene chloR1de. After 3 hours at ambient temperature, the reaction medium is hydrolyzed and then extracted with methylene chloR1de. The organic phase is dR1ed over magnesium sulfate, filtered and evaporated. PuR1fication of the crude product by chromatography on silica (eluent: ethylacetate/hexane (80/20, v/v)) makes it possible to obtain 21 mg of butyl[6-chloro-5-phenyl-1 -(2-(tR1methylsilanyl)ethoxymethyI-1 H-indazol-3-yl]amine (yellow solid). Mass spectrum: 432 [M+H]+; retention time: 5.26 minutes. "H NMR [dfi-DMSO]: 7.83 (1H, s), 7.73 (1H, s), 7.35-7.50 (5H, m), 6.25 (1H, t, J = 6 Hz), 5.49 (2H, s), 3.52 (2H, t, J = 8 Hz), 3.24 (2H, m), 1.60 (2H, m), 1.39 (2H, m), 0.91 (3H, t, J = 7 Hz), 0.81 (2H, t, J = 8 Hz), -0.07 (9H, s). Stage 2: 0.7 ml of 2N HC1 is added to a solution of 21mg of butyl[6-chloro-5-phenyl-l-(2-(tR1methylsilanyl)ethoxymethyl)-lH-indazol-3-yl]amine in 0.3 cm3 of methanol. The reaction medium is stirred at ambient temperature for 48 hours and at reflux for 1 hour, then evaporated. The solid obtained is dR1ed under vacuum to give 16 mg of N-butyl-6-chloro-5-phenyl-lH-indazol-3-amine (yellow solid). Mass spectrum: 300[M+H]+; retention time: 4.25 minutes. "H NMR [d6-DMSO]: 7.52 (1H, s), 7.95(1H, s), 7.35-7.50 (5H, m), 3.30 (2H, t, J = 7 Hz), 1.61 (2H, m), 1.40 (2H, m), 0.92 (3H, t, J = 7 Hz). Example A2: 3-(6-Chloro-5-phenyl-lH-indazol-3-ylamino)thiophene-2-carbonitR1le 38 mg of 2-dicyclohexylphosphino-2"-(N,N-dimethylamino)biphenyl, 20 mg of Pd2dba3 (tR1s(dibenzylideneacetone)dipalladium(O)), 52 mg of 2-cyano 3-bromo thiophene and 23 mg of sodium tert-butoxide are added to 52 mg of the compound 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 0.5 ml of NMP (l-methyl-2-pyrrolidone). The reaction is placed under microwaves at 140°C for 3 min. After the usual treatments, the crude product is treated with 2N HC1 in methanol to give, after puR1fication, 8.4 mg of 3-(6-chloro-5-phenyl-lH-indazol-3-ylamino)thiophene-2-carbonitR1le. Mass spectrum: 351[M+H]+; retention time: 4.19 minutes. "H NMR [d6-DMSO]:7.40 (1H, m), 7.48 (2H, m), 7.53 (3H, m), 7.81 (1H, s), 8.09 (1H, s), 8.27 (1H, d, J = 5.5 Hz), 8.91 (2H, s). Stage 1: 39 ul of phenyl isocyanate are added to a solution of 102.2 mg of 3-amino-5- phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 2.5cm3 of tetrahydrofuran. The reaction medium is stirred at ambient temperature for 24 hours and is then evaporated. PuR1fication of the crude product by chromatography on silica (eluant: methylene chloR1de/acetone (98/2, v/v)) makes it possible to obtain 122.5mg of l-[6-chloro-5-phenyl-l-(2-tR1methylsilanylethoxymethyl)-lH-indazol-3-yl]-3- phenylurea (colorless solid). Mass spectrum: 493[M+H]+; retention time: 6.02 minutes. "H NMR [de-DMSO]: 9.89 (1H, broad s), 9.86(1H, broad s), 8.20 (1H, s), 8.07 (1H, s), 7.35-7.50 (5H, m), 5.81 (2H, s), 3.66 (2H, t, J = 8 Hz), 0.92 (2H, t, J = 8 Hz), -0.12 (9H, s). Stage 2: 1 ml of 2N HC1 is added to a solution of 106 mg of l-[6-chloro-5-phenyl-l-(2-tR1methylsilanylethoxymethyl)-lH-indazol-3-yl]-3-phenylurea in 12cm3 of methanol. The reaction medium is stirred at ambient temperature for 48 hours and at reflux for 5 hours, then evaporated. The solid obtained is dR1ed under vacuum to give 82 mg of N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-phenylurea (colorless solid). Mass spectrum: 363 [M+H]+; retention time: 5.15 minutes. ]H NMR [de-DMSO]: 12.64 (1H, broad s), 9.70(1H, broad s), 9.59 (1H, broad s), 8.07 (1H, s), 7.64 (1H, s), 7.50 (7H, m), 7.30 (2H, m), 7.0 (1H, m). Example B2: l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(4-ethoxyphenyl)urea 36.4 mg of 4-ethoxyphenyl isocyanate are added to 80 mg of 3-amino-5-phenyl-6- chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 1 ml of THF. The mixture is heated at 50°C for 1 h and is then hydrolyzed in a saturated KH2PO4 solution and extracted with methylene chloR1de. After drying and evaporating, the crude product is puR1fied by chromatography on silica with an AcOEt/hexane mixture. The product obtained is deprotected in 2 ml of a 1/1 MeOH/2N HCL mixture at reflux for 3h. 62.5 mg of l-(6-chloro-5-phenyl-lH-indazol-3-yl)-3-(4-ethoxyphenyl)urea are obtained. Mass spectrum: 407 [M+H]+; retention time: 4.36 minutes XE NMR [d6-DMSO]: 1.3 (3H, t, J = 7 Hz), 3.98 (2H, q, J = 7 Hz), 6.87 and 7.36 (AA"-BB", 4H), 7.36-7.50 (5H, m), 7.63 (1H, s), 8.08 (1H, s), 9.53 (2H, s), 12.53 (lH,s) Stage 1: 62 \x\ of pyR1dine and 125 u.1 of ethyl chloroformate are successively added to 387.8 mg of 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 2 ml of methylene chloR1de. The reaction is completed after 75 mn. After hydrolysis, extraction and evaporation, 571 mg of crude carbamate, (6-chloro-5-phenyl-lH-indazol-3-yl)carbamic acid ethyl ester, are obtained. Stage 2: 311 mg of 4-(3-aminopropyl)-l-methylpiperazine are added to 106mg of the preceding carbamate in 2.5 ml of tR1fluorotoluene and the reaction is carR1ed out under microwave radiation at 200°C for 20 min. After puR1fying by preparative LC/MS (acetonitR1le/pH=9 buffer), 60 mg of l-[6-chloro-5-phenyl-l-(2-tR1methylsilanyl)- ethoxymethyl)-lH-indazol-3-yl]-3-[3-(4-methylpiperazin-l-yl)propyl]urea are obtained. Stage 3: The preceding compound is taken up in 2 ml of a 1/1 MeOH/2N HC1 mixture and is brought to reflux for 3h. "H NMR [de-DMSO]: 1.63 (2H, m), 2.18 (3H, s), 2.33 (10H, m), 3.21 (2H, m), 7.36-7.48 (5H, m), 7.58 (1H, s), 7.66 (1H, t, J = 5.5 Hz), 8.08 (1H, s), 9.37 (1H, s), 12.70 (1H, s). 33 mg of methyl acetimidate are added to 50 mg of 3-amino-6-chloro-5-phenyl-lH-indazole in 3 ml of acetonitR1le and 12 mg of acetic acid. The reaction is placed under microwave radiation at 180°C for 5 min. After the usual treatments and puR1fication through silica, 35 mg of N-(6-chloro-5-phenyl-lH-indazol-3-yl)acetamidine are obtained. Stage 1: 0.236 cm3 of pyR1dine and 26.5 mg of 3-methoxyphenylsulfonyl chloR1de are added to a solution of 54.1 mg of 3-amino-5-phenyl-6-chloro-l-[(2-tR1methylsilylethoxy)methyl]indazole in 2ml of methylene chloR1de. The reaction medium is stirred at ambient temperature for 24 hours and then evaporated. The puR1fication of the crude product by chromatography on silica (eluent: methylenechloR1de/acetone (98/2, v/v)) makes it possible to obtain 70 mg of lN-[6-chloro-5-phenyl-l-(2-(tR1methylsilanyl)ethoxymethyl)-lH-indazol-3-yl]-3-methoxybenzenesulfonamide (colorless foam). Mass spectrum: 546[M+H]+; retention time: 4.24 minutes. "H NMR [de-DMSO]: 10.96 (1H, s), 7.37 (1H, s), 7.58 (1H, s), 7.30-7.55 (8H, m), 7.17 (1H, dd), 5.63 (2H, s), 3.74 (3H, s), 3.38 (2H, t, J=8Hz), 0.74 (2H, t, J=8Hz), -0.12 (9H,s). Stage 2: 1 cm3 of 2N HC1 is added to a solution of 10.8mg of lN-[6-chloro-5-phenyl-1-(2-(tR1methylsilanyl)ethoxymethyl)-1 H-indazol-3-yl]-3 - methoxybenzenesulfonamide in 1cm3 of methanol. The reaction medium is stirred at ambient temperature for 48 hours and at reflux for 1 hour, then evaporated. The solid obtained is dR1ed under vacuum to give 8 mg of N-(6-chloro-5 -phenyl- lH-indazol-3-yl)-3-methoxybenzenesulfonamide (colorless solid). Mass spectrum: 414[M+H]+; retention time: 4.04 minutes. "H NMR [de-DMSO]: 12.90 (1H, broad s), 10.74(1H, broad s), 7.67 (1H, s), 7.31-7.56 (10H, s), 7.20 (1H, dd), 3.77 (3H, s). The pharmaceutical compositions according to the invention are composed of a compound of formula (I) or a salt of such a compound, in the pure state or in the form of a composition in which it is combined with any other pharmaceutically compatible product, which can be inert or physiologically active. The medicaments according to the invention can be employed orally, parenterally, rectally or topically. Use may be made, as solid compositions for oral administration, tablets, pills, powders (of hard gelatin capsules, cachets) or granules. In these compositions, the active pR1nciple according to the invention is mixed with one or more inert diluents, such as starch, cellulose, sucrose, lactose or silica, under an argon stream. These compositions can also compR1se substances other than the diluents, for example one or more lubR1cants, such as magnesium stearate or talc, a colorant, a coating (dragees) or a glaze. Use may be made, as liquid compositions for oral administration, of pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs compR1sing inert diluents, such as water, ethanol, glycerol, vegetable oils or liquid paraffin. These compositions can compR1se substances other than the diluents, for example wetting, sweetening, thickening, flavoR1ng or stabilizing products. The steR1le compositions for parenteral administration can preferably be solutions in aqueous or nonaqueous form, suspensions or emulsions. Use may be made, as solvent or vehicle, of water, propylene glycol, a polyethylene glycol, vegetable oils, in particular olive oil, injectable organic esters, for example ethyl oleate, or other suitable organic solvents. These compositions can also compR1se adjuvants, in particular wetting, isotonizing, emulsifying, dispersing and stabilizing agents. SteR1lization can be carR1ed out in several ways, for example by aseptic filtration, by incorporating steR1lizing agents in the composition, by irradiation or by heating. They can also be prepared in the form of steR1le solid compositions which can be dissolved at the time of use in steR1le water or any other injectable steR1le medium. The compositions for rectal administration are suppositoR1es or rectal capsules which compR1se, in addition to the active product, excipients such as cocoa butter, semisynthetic glyceR1des or polyethylene glycols. The compositions for topical administration can be, for example, creams, lotions, eye drops, mouthwashes, nose drops or aerosols. A subject matter of the invention is the compounds and their use of aminoindazoles of formula (I) and their pharmaceutically acceptable salts in the preparation of pharmaceutical compositions intended to prevent and treat diseases which result from an abnormal activity of kinases, such as, for example, those involved in neurodegenerative diseases, Alzheimer"s disease, Parkinson"s disease, frontopaR1etal dementia, corticobasal degeneration, Pick"s disease, strokes, cranial and spinal traumas and peR1pheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaR1es syndrome, syndrome X, immunodeficiency and cancer. Mention may be made, as abnormal kinase activity, of, for example, that of PI3K, AkT or GSK3beta, of CDKs, and the like. In human therapy, the compounds according to the invention are of particular use in the treatment and/or prevention of neurodegenerative diseases, Alzheimer"s disease, Parkinson"s disease, frontopaR1etal dementia, corticobasal degeneration, Pick"s disease, strokes, cranial and spinal traumas and peR1pheral neuropathies, obesity, metabolic diseases, type II diabetes, essential hypertension, atherosclerotic cardiovascular diseases, polycystic ovaR1es syndrome, syndrome X, immunodeficiency and cancer. The doses depend on the desired effect, on the duration of the treatment and on the administration route used; they are generally between 5 mg and 1000 mg per day orally for an adult with unit doses ranging from 1 mg to 250 mg of active substance. Generally, the doctor will determine the appropR1ate dosage according to the age, weight and all the other factors specific to the subject to be treated. The following examples illustrate compositions according to the invention: The present invention also relates to the method for the prevention and treatment of diseases in which a phosphorylation of the tau protein is involved by administration of a compound of formula (I) and its pharmaceutically acceptable salts. WE CLAIM: 1. A compound of formula (I): in which R3 is a (l-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl( I -6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SRI, S(O)Rl, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -S02-0-Rl, aryl, heteroaryl, formyl, oxo, trifluoromethyl. trifluoromethylsulfanyl, trifluoromethoxy or (1- 6C)alkyl: R5 is an aryl optionally substituted by 1 or more substituents chosen from halogen, CN. NO:, NH2, OH. OR10, COOH, C(O)OR10, -O-C(O)R10, NR10R11, NHC(O)R10, C(O)NR10Rll, NHC(S)R10, C(S)NR10R11, SR10, S(O)R10, SO2R10, NHSO2R10, SO2NR10Rll, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, trifluoromethyl, trifluoromethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, trifluoromethyl, ethylenyl, acetylenyl, trifluoromethoxy, N02, NH2 or NMe2 radical; Rl, R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (1-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, trifluoromethyl or trifluoromethoxy; Rl and R2 can form a 5- or 6-membered ring which may or may not have a hereroatom, such as O, S or N: its racemates, enantiomers or diastereoisomers and.their mixtures, its tautomers and its pharmaceutically acceptable salts. 2. A compound of formula (I): in which R3 is a(1-6C)alkyl, aryl, aryl(l-6C)alkyl, heteroaryl, heteroaryl(l-6C)alkyl, aryl or heteroaryl fused to a (1-10C) cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, CSNR1R2, COOR1, S02R1 or C(=NH)NR1 radical; these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, N02, NH2, OH, OR1, COOH, C(0)ORl, -O-C(0)R1, NR1R2, NHC(0)R1, C(0)NR1R2, SR1, S(0)R1, S02R1, NHS02R1, S02NR1R2, C(S)NR1R2, \"HC(S)R1. -0-S02Rl, -S02-0-RL aryl, heteroaryl, formyl. oxo, trifluoromethyl. trifluoromethylsulfanyl, trifluoromethoxy or (I-6C)alkyl; R5 is a phenyl optionally substituted by 1 or more substituents chosen from halogen, CN. N02) NH2, OH. OR10, COOH, C(O)OR10, -O-C(O)Rl0, NR10R11, NHC(O)R10, C(O)NRl0Rll, NHC(S)R10, C(S)NR10R11, SR10, S(O)Rl0, SO2R10, NHS02Rl0, SO2NR10RU, -O-SO2R10, -SO2-O-R10, aryl, heteroaryl, formyl, trifluoromethyl, trifluoTomethoxy or (l-6C)alkyl; R6 is a halogen, methyl, cyclopropyl, CN, OH, methoxy, trifluoromethyl, ethylenyl, acetylenyl, trifluoromethoxy, N02, NH2 or NMe2 radical; Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, oxo, trifluoromethyl or trifluoromethoxy; Rl and R2 can form a 5- or 6-membered ring which may or may not have a heteroatom, such as O, S or N; its racemates, enantiomers or diastereoisomers and their mixtures, its tautomers and its pharmaceutically acceptable salts. 3. The compound as claimed in claim 1, which is chosen from: N-(bicyclo[2.2.1]hept-5-en-2-ylmethyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3,3-dimethylbutyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3 -phenylpropyl)-5-phenyl-1 H-indazol-3 -amine 6-chloro-N-(cyclopropylmethyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(cyclopentylmethyl)-5-phenyl-1 H-indazol-3-amine 6-chIoro-N-[3-(methylthio)propyI]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(cyclohexylmethyl )-5-phenyl-l H-indazol-3-amine 6-chloro-N-propyl-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(2,2,3,3,4,4,4-heptafluorobutyl)-5-phenyl-lH-indazol-3-amine hydrate 6-chloro-N-(4,4,4-trifluorobup. !)-5-phenyl-l H-indazol-3-amine 6-chloro-N-[(4-methoxyphenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(phenylmethyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(4-cyanophenyl)methyl]-5-phenyl-lH-indazol-3-amine N-[(4-chlorophenyl)methyl]-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(3-methoxyphenyl)methyl]-5-phenyl-lH-mdazol-3-amine 6-chIoro-N-[[4-(trifluoromethoxy)phenyl]methyl]-5-phenyl-IH-indazol-3-amine N-[4-[t[6-chloro-5-phenyl-lH-indazoI-3-yl]amino]methyl]phenyl]acetamide 6-chloro-N-[(3,5-dichlorophenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[4-(trifluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-N-[(4-fluorophenyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-(4-methylphenoxy)phenylmethyl]-5-phenyl-l H-indazol-3-amine N-(2,2,3.3,4,4,4-heptafluorobutyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[3-(trifluoromethyl)phenyl]methyl]-lH-indazol-3-amine 6-chloro-N-[(6-methoxy-2-naphthyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N"-[(pentafluorophenyl)methyl]-5-phenyl-lH-indazoI-3-amine 6-chloro-N"-[[4-(methylthio)phenyl]methyl]-5-phenyl-lH-indazol-3-amine N-[(4-chloro-3-fluorophenyl)methyl]-6-chloro-5-phenyl-lH-indazol-3-amine 6-chIoro-5-phenyl-N-(3,3,3-trifluoropropyl)-lH-indazoI-3-amine 6-chloro-5-phenyl-N-(3-thienylmethyl)-lH-indazol-3-arnine N-(bicyclo[2.2.1 ]hept-5-en-2-ylmethyl)-6-chloro-5-phenyl-1 H-indazol-3-amine N-(l,I"-biphenyl-4-ylmethyl)-6-chloro-5-phenyl-lH-indazol-3-amine 6-chloro-N-[[4-(dimethyiamino)phenyl]methyl]-5-phenyl-lH-indazol-3-amine N-(2.2"-bithiophen-5-ylmethyh-6-chloro-5-phenyl-lH-indazol-3-amine 6-chIoro-5-phenyl-N-[[l-(phenylmethyl)-lH-imidazol-2-yl]methyl]-lH-indazol-3-amine 6-chloro-N-[[l-methyl-lH-imidazol-2-yl]methyl]-5-phenyI-lH-indazol-3-amine 6-chloro-N-[(l-methyl-lH-indol-3-yl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[(5-methyl-2-furanyl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-( 1 H-pyrrol-2-ylmethyl)-l H-indazol-3-amine 6-chloro-5-phenyl-N-[(lH-imidazol-2-yl)methyl]-lH-indazol-3-amine 6-chIoro-5-phenyI-N-[( 1 H-imidazol-4-yl)methyl]-1 H-indazol-3-arnine 6-chloro-5-phenyl-N-(lH-pyrazol-3-ylmethyl)-lH-indazol-3-amine 6-chloro-N-[[2-methyl-lH-imidazoU4-yl]methyl]-5-phenyI-lH-indazol-3-amine 6-chloro-N-[(3,5-dimethyl-l-phenyl-lH-pyrazol-4-yl)methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[[2-phenyl-lH-imidazol-4-yl]methyl]-lH-indazol-3-amine 6-chloro-N-[[5-(4-chlorophenyl)-2-furanyI]methyl]-5-phenyl-lH-indazol-3-amine 6-chloro-5-phenyl-N-[(l-methyl-lH-pyrrol-2-yl)methyl]-lH-indazol-3-amine 4-[5-[[[6-chloro-5-phenyl-lH-indazol-3-yl]amino]methyl]-2-furanyl]-benzenesu 1 fonamide 6-chloro-5-phenyl-N-(3-thienylmethyl)-lH-indazol-3-amine 6-chIoro-5-phenyl-N-[[2-phenyl-lH-imidazol-4-yl]methyl]-lH-indazol-3-amine ethyl 2-[[[6-chloro-5-phenyl-lH-indazol-3-yl]amino]methyl]-5-(methylthio)-lH- imidazole-4-carboxylate 6-chloro-5-phenyl-N-[[5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl]-lH-indazol-3-amine 6-chloro-5-phenyl-N-[2-( 1 -piperidinyl)ethyl]-1 H-indazol-3-amine 6-chloro-N-[2-(4-morpholin>l)ethyl]-5-phenyl-lH-indazol-3-amine N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(3,5-dichlorophenyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(2-propenyl)urea N-(6-chloro-5-phenyl-1 H-indazol-3-yl)-N"-(phenylmethyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-phenoxyphenyl)urea N-(6-chloro-5-phenyMH-indazol-3-yl)-N"-[(4-methoxyphenyl)methyl]urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-[4-(trifluoromethyl)phenyl]urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-methoxyphenyl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yI)-N"-cyclohexyIurea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-propylurea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-chlorophenyl)urea N-(6-chloro-5-phenyl-1 H-indazol-3-yl)-N"-(4-fluorophenyl)urea N-[6-chloro-5-phenyl-lH-indazol-3-yl]-N"-(tricyclo[3.3.1.1"" ]dec-l-yl)urea N-(6-chloro-5-phenyl-lH-indazol-3-yl)-N"-(4-methylphenyl)urea N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methyl-benzenesulfonamide N-[6-chloro-5-phenyl-1 H-indazol-3-yl]methanesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-2-propanesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-2,2,2-trifluoroethanesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-2-thiophenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]benzenesulfonamide N"-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-(trifluoromethyl;benzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-5-(3-isoxazolyl)-2-thiophenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-fIuorobenzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methoxybenzenesulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]benzenemethanesulfonamide N-[6-chloro-5-phenyl-l H-indazol-3-yl]-l -methyl-1 H-imidazole-4-sulfonamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-(l,l-dimethylethyl)benzenesulfonamide N-[4-[[(6-chloro-5-phenyl-lH-indazol-3-yl)amino]sulfonyl]phenyl]acetamide N-[6-chloro-5-phenyl-lH-indazol-3-yl]-4-methylbenzenemethanesulfonamide 6-chloro-N-(pentafluorophenyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(3,4-difluorophenyl)-5 -phenyl-1 H-indazol-3 -amine 6-chloro-5-phenyl-N-(2,3,5,6-tetrafluorophenyl)-lH-indazol-3-amine 6-chloro-5-phenyl-N-(2,4,6-trifluorophenyl)-lH-indazol-3-amine 6-chIoro-N-(4-fluorophenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-(trifluoromethyl)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[4-(trifluoromethyl)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-[3-fluoro-5-(trifluoromethyI)phenyl]-5-phenyl-lH-indazol-3-amine 6-chloro-N-(4-nitrophenyl)-5-phenyl-1 H-indazol-3-amine 6-chloro-N-(3-nitrophenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(3-methoxyphenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(4-methoxyphenyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N,5-diphenyl-lH-indazol-3-amine 6-chloro-N-(l-pyridinyl)-5-phenyl-lH-indazol-3-amine 6-chloro-N-(2-pyridinyl)-5-phenyl-1 H-indazol-3-amine their racemates, enantiomers or diastereoisomers and their mixtures, their tautomers and their pharmaceutically acceptable salts. 4. The compound as claimed in any one of claims 1 to 3, which is chosen from: N-butyl-6-chloro-5-phenyl-1 H-indazol-3 -amine 3-(6-Chloro-5-phenyl-lH-indazol-3-ylamino)thiophene-2-carbonitrile (6-Chloro-5 -phenyl-1 H-indazol-3 -yl)(pyridin-2-yl)amine (6-Chloro-5-phenyl-lH-mdazol-3-yl)(5-nitropyridin-2-yl)amine (6-Chloro-5-phenyl-lH-indazol-3-yl)(6-methoxypyridin-2-yl)amine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)-N"-phenylurea 1 -(6-Chloro-5-phenyl-l H-indazol-3-yl)-3-(4-ethoxyphenyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3,4-dichlorophenyl)urea 3-[3-(6-Chloro-5-phenyl-lH-indazol-3-yl)ureido]propionic acid methyl ester 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-(4-(dimethylamino)phenyl)urea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-isopropylurea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-cyclohexylurea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3-(trifluoromethyl)phenyl)urea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-(2-(thiophen-2-yl)ethyl)urea 1 -(1,3-Benzodioxol-5-yl)-3-(6-chloro-5-phenyl-lH-indazol-3-yl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3,5-dimethylisoxazol-4-yl)urea 1 -Benzyl-3 -(6-chloro-5-phenyl-1 H-indazol-3-yl)urea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-(phenethyl)thiourea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-[3-(4-methylpiperazin-1 -yl)propyl]urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3-(imidazol-l-yl)propyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(2-hydroxyethyl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-[3-(4-methylpiperazin-l-yl)propyl]urea Pyrrolidine-1 -carboxylic acid (6-chloro-5-phenyl-1 H-indazoI-3-yI)amide (6-Chloro-5-phenyI-lH-indazoI-3-yl)carbamic acid methyl ester (6-Chloro-5-phenyl-1 H-indazol-3-yl)urea (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid benzyl ester (6-Chloro-5-phenyl-l H-indazol-3-yl)carbamic acid allyl ester (6-Chloro-5-phenyl-lH-indazol-3-yl)carbamic acid isobutyl ester Piperidine-1-carboxylic acid (6-chloro-5-phenyl-l H-indazol-3-yl)amide 1 -(3-(Azetidin-1 -yl)propyl)-3-(6-chloro-5-phenyl-1 H-indazol-3-yl)urea l-(6-Chloro-5-phenyl-lH-indazol-3-yl)-3-(3-chloropropyl)urea 1-(6,7-Difluoro-5-phenyl-1 H-indazol-3-yl)-3-(3-(imidazol-1-yl)propyI)urea 1 -(3-Aminopropyl)-3-(6-chloro-5-phenyl-l H-indazol-3-yl)urea 1 -(6-Chloro-5-phenyl-1 H-indazol-3-yl)-3-[4-(4-(pyridin-3-yl)imidazol-1 -yl)-butyl]urea 1 -(6-ChIoro-5-phenyl-1 H-indazol-3-yl)-3-(2-(pyrrolidin-1 -yl)ethyl)urea 2,5-Dimethylpyrrolidine-l-carboxylic acid (6-chloro-5-phenyl-lH-indazol-3-yl)-amide N-(6-Chloro-5-phenyl-1 H-indazol-3-yl)acetamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)-6-methoxypyrazine-2-carboxamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)benzamidine N-(6-Chloro-5-phenyl-lH-indazol-3-yl)pyridine-2-carboxamidine N-(6-chloro-5-phenyl-lH-indazol-3-yl)-3-methoxybenzenesulfonamide their racemates, enantiomers or tautomers, and their pharmaceutically acceptable salts. 5. A process for the preparation of the compound of formula (I) as claimed in claim 1 and for which R3 is (l-6C)alkyl, aryl(l-6C)alkyl, heteroaryl( 1-6C)alkyl, heterocycloalkyl, cycloalkyl or polycycloalkyl, these radicals optionally being substituted by 1 or more substituents chosen from halogen, CN, NO2, NH2, OH, OR1, COOH, C(0)ORl, -0-C(0)Rl, NR1R2, NHC(0)R1, C(0)NR1R2, SRI, S(0)R1, SO2RI, NHSO2RI, S02NR1R2, C(S)NR1R2, NHC(S)R1, -0-S02Rl, -SO2-O-RI, aryl, heteroaryl, formyl, trifluoromethyl, trifluoromethylsulfanyl, trifluoromethoxy or (l-6C)alkyl and Rl and R2 are, independently of one another, a hydrogen, (1- 6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted or unsubstituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, NO2, NH2, OH, COOH, COOalkyl, CONH2, formyl, trifluoromethyl or trifluoromethoxy; from a derivative of formula (I) where R3 is H, from a derivative of RICHO and from sodium triacetoxyborohydride in dichloromethane, and the product obtained is preferably converted to a pharmaceutically acceptable salt. 6. The process for the preparation of the compound of formula (I) as claimed in claim 1 and for which R3 is CONR1R2 and Rl and R2 are, independently of one another, a hydrogen, (l-6C)alkyl, aryl. alkenyl, alkynyl or heteroaryl, themselves optionally or unsubstituted being substituted/by 1 or more .substituents ,chosen_from halogen. (l-6C)alkyl, (L- 6C)alkoxy, CN, N02, NH2, OH, COOH, COOalkyl, CONH2, formyl, trifluoromethyl or trifluoromethoxy, from OCNR1 and from a derivative of formula (I) where R3 is H in tetrahydrofuran, and the product obtained is optionally converted to a pharmaceutically acceptable salt. 7. The process for the preparation of the compound of formula (I) as claimed in claim 1 and for which R3 is SO2R1 and Rl is a hydrogen, (l-6C)alkyl, aryl, alkenyl, alkynyl or heteroaryl, themselves optionally being substituted by 1 or more substituents chosen from halogen, (l-6C)alkyl, (l-6C)alkoxy, CN, N02, NH2, OH, COOH. COOalkyl, CONH;. formyl, trifluoromethyl or trifluoromethoxy, from a sulfonyl chloride RlSO:Cl and from a derivative of formula (I) where R3 is H and dichloromethane in the presence of a base, and the compound obtained is preferably converted to a pharmaceutically acceptable salt. 8. The pharmaceutical composition, which comprises, in a pharmaceutically acceptable medium, a compound defined as claimed in any one of claims 1 to 4.

Documents:

0325-chenp-2005 abstract.jpg

0325-chenp-2005 abstract.pdf

0325-chenp-2005 claims-duplicate.pdf

0325-chenp-2005 claims.pdf

0325-chenp-2005 correspondence-others.pdf

0325-chenp-2005 correspondence-po.pdf

0325-chenp-2005 description (complete)-duplicate.pdf

0325-chenp-2005 description (complete).pdf

0325-chenp-2005 form-1.pdf

0325-chenp-2005 form-26.pdf

0325-chenp-2005 form-3.pdf

0325-chenp-2005 form-5.pdf

0325-chenp-2005 pct-search report.pdf

0325-chenp-2005 pct.pdf

0325-chenp-2005 petition.pdf